[Role of arsenolite on 8-isoprostane of asthmatic mice plasm].
OBJECTIVE
Through the establishment of mouse' ovalbumin- sensitized asthmatic model and the observation of the 8-Isoprostane of plasm, to evaluate the therapeutic effects of arsenolite on asthmatic mice.


METHODS
Forty-two healthy Kunming male mice were randomly divided into control group and experience groups, the latter were treated with dexamethasone, arsenolite. Lung function were tested, 8-isoprostane of plasm and WBC of BALF were measured.


RESULTS
Lung function improved after treating with dexamethasone or arsenolite. The WBC of asthmatic mice were significantly higher than those in control group, and decreased after treating with dexamethasone or arsenolite; 8-Isoprostane of plasm in asthmatic mice was higher than that of control group, and decreased after treating with dexamethasone or arsenolite.


CONCLUSIONS
There is oxidant stress status in asthmatic mice. Arsenolite could lighten airway obstruction, reduce airway high response and redress oxidant stress status in asthmatic mice.
Li
Dong-ming
DM
Department of Respiratory Disease, Guangdong Medical College, Zhanjiang 524001, China. lizewei@gdmc.edu.cn
Xie
Jia-xing
JX
Liang
Biao
B
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D001249:Asthma / Q000097:blood* / Q000139:chemically induced / Q000503:physiopathology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000097:blood; D007958:Leukocyte Count; D008297:Male; D008419:Materia Medica / Q000494:pharmacology*; D051379:Mice; D010047:Ovalbumin; D010087:Oxides / Q000494:pharmacology*; D011897:Random Allocation; D012129:Respiratory Function Tests
D018927:Anti-Asthmatic Agents; D001152:Arsenicals; D008419:Materia Medica; D010087:Oxides; C075750:8-epi-prostaglandin F2alpha; D010047:Ovalbumin; D015237:Dinoprost; D000077237:Arsenic Trioxide